Both IgG4 monoclonal antibodies target programmed death receptor-1 (PD-1) on the cytotoxic CD8+ T-lymphocytes, diminishing inhibitory signals from the programmed death ligand-1 (PD-L1) exhibited on the cancer cell surface [166,167]. Here, CD8A is linked to cancer.